The future of mood-disorder research: covering identification of new therapeutic targets, preclinical models, and medicinal chemistry opportunities.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Chad E. Beyer is Prinicpal Research Scientist II at Pfizer Global Research and Development, Princeton, New Jersey and Adjunct Professor at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of California San Diego, San Diego, California, and Neuroscience Education Institute, Carlsbad, California, USA.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Better World Books, Mishawaka, IN, USA
Zustand: Very Good. 1st Edition. Pages intact with possible writing/highlighting. Binding strong with minor wear. Dust jackets/supplements may not be included. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good. Artikel-Nr. 56641004-6
Anzahl: 1 verfügbar
Anbieter: Antiquariaat Die Sammlung, Amsterdam Zuidoost, Niederlande
Hardcover. Zustand: Fine. 1st Edition. 137 p. Artikel-Nr. BK 1-3 450
Anzahl: 1 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In English. Artikel-Nr. ria9780521760584_new
Anzahl: Mehr als 20 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. The future of mood-disorder research: covering identification of new therapeutic targets, preclinical models, and medicinal chemistry opportunities. Editor(s): Beyer, Chad E.; Stahl, Stephen M. Num Pages: 150 pages, 27 b/w illus. 10 tables. BIC Classification: MMGW. Category: (P) Professional & Vocational. Dimension: 242 x 156 x 62. Weight in Grams: 454. . 2010. New. hardcover. . . . . Books ship from the US and Ireland. Artikel-Nr. V9780521760584
Anzahl: Mehr als 20 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice. Artikel-Nr. 9780521760584
Anzahl: 2 verfügbar